procurcumenol: RN given for (1S-(1alpha,3abeta,8aalpha))-isomer; epiprocurcumenol is the (1S-(1alpha,3aalpha,8aalpha))-isomer; a TNF-alpha antagonist isolated from Curcuma zedoaria; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 189061 |
| CHEMBL ID | 2332430 |
| CHEBI ID | 168250 |
| SCHEMBL ID | 3297651 |
| MeSH ID | M0404449 |
| Synonym |
|---|
| CHEBI:168250 |
| 21698-40-8 |
| (3s,3as,8ar)-3-hydroxy-3,8-dimethyl-5-propan-2-ylidene-2,3a,4,8a-tetrahydro-1h-azulen-6-one |
| procurcumenol |
| rhbohexdguviiy-whofxgatsa- |
| inchi=1/c15h22o2/c1-9(2)12-8-13-11(5-6-15(13,4)17)10(3)7-14(12)16/h7,11,13,17h,5-6,8h2,1-4h3/t11-,13-,15-/m0/s1 |
| bdbm50429858 |
| (1s,3ar,8as)-1-hydroxy-1,4-dimethyl-7-propan-2-ylidene-3,3a,8,8a-tetrahydro-2h-azulen-6-one |
| CHEMBL2332430 , |
| SCHEMBL3297651 |
| 3-hydroxy-3,8-dimethyl-5-(propan-2-ylidene)-2,3,3a,4,5,8a-hexahydroazulen-6(1h)-one |
| DTXSID80944312 |
| (3s,3as,8ar)-3-hydroxy-3,8-dimethyl-5-(propan-2-ylidene)-1,2,3,3a,4,5,6,8a-octahydroazulen-6-one |
| AKOS040760648 |
| FS-7871 |
| (1s,3ar,8as)-2,3,3a,7,8,8a-hexahydro-1-hydroxy-1,4-dimethyl-7-(1-methylethylidene)-6(1h)-azulenone |
| 6(1h)-azulenone, 2,3,3a,7,8,8a-hexahydro-1-hydroxy-1,4-dimethyl-7-(1-methylethylidene)-, (1s,3ar,8as)- |
| C46YDH55ZN |
| guaia-7(11),9-dien-8-one, 4-hydroxy- |
| CS-0086608 |
| HY-124474 |
| Class | Description |
|---|---|
| sesquiterpenoid | Any terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 26.8000 | 0.7000 | 4.5804 | 9.4500 | AID729839 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 45.6000 | 0.0005 | 3.4984 | 9.7600 | AID729840 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID729839 | Inhibition of TCPTP (unknown origin) assessed as decrease in p-nitrophenol production from pNPP substrate after 30 mins by HTS7000 bioassay reader analysis | 2013 | Journal of natural products, Feb-22, Volume: 76, Issue:2 | Sesquiterpenes from the rhizomes of Curcuma heyneana. |
| AID729841 | Inhibition of PTP1B (unknown origin) assessed as decrease in p-nitrophenol production from pNPP substrate at 25 ug/ml after 30 mins by HTS7000 bioassay reader analysis | 2013 | Journal of natural products, Feb-22, Volume: 76, Issue:2 | Sesquiterpenes from the rhizomes of Curcuma heyneana. |
| AID751215 | Cytotoxicity against mouse RAW264.7 cells at IC50 by MTT assay | 2013 | Journal of natural products, Jun-28, Volume: 76, Issue:6 | Guaiane-type sesquiterpenes from Curcuma phaeocaulis and their inhibitory effects on nitric oxide production. |
| AID751214 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay | 2013 | Journal of natural products, Jun-28, Volume: 76, Issue:6 | Guaiane-type sesquiterpenes from Curcuma phaeocaulis and their inhibitory effects on nitric oxide production. |
| AID1504878 | Antioxidant activity against H2O2-induced cell damage in rat PC12 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay (Rvb = 64.34 +/- 1.02 %) | 2017 | Journal of natural products, 12-22, Volume: 80, Issue:12 | Sesqui- and Diterpenoids from the Radix of Curcuma aromatica. |
| AID729840 | Inhibition of PTP1B (unknown origin) assessed as decrease in p-nitrophenol production from pNPP substrate after 30 mins by HTS7000 bioassay reader analysis | 2013 | Journal of natural products, Feb-22, Volume: 76, Issue:2 | Sesquiterpenes from the rhizomes of Curcuma heyneana. |
| AID1504880 | Antioxidant activity against H2O2-induced cell damage in rat PC12 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay (Rvb = 64.34 +/- 1.02 %) | 2017 | Journal of natural products, 12-22, Volume: 80, Issue:12 | Sesqui- and Diterpenoids from the Radix of Curcuma aromatica. |
| AID1504879 | Antioxidant activity against H2O2-induced cell damage in rat PC12 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay (Rvb = 64.34 +/- 1.02 %) | 2017 | Journal of natural products, 12-22, Volume: 80, Issue:12 | Sesqui- and Diterpenoids from the Radix of Curcuma aromatica. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.54) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||